Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors

Investigational New Drugs

Volumn 22, Issue 4, 2004, Pages 449-458

  Undevia, Samir D ^a   Vogelzang, Nicholas J ^a   Mauer, Ann M ^a   Janisch, Linda ^a   Mani, Sridhar ^a   Ratain, Mark J ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b Comm Clin P   (United States)

Author keywords

CEP 2563; maximum tolerated dose; pharmacokinetics; phase I clinical trial; toxicity

Indexed keywords

CEP 2547; CEP 2563; CEP 701; CEP 751; DEXAMETHASONE; DIPHENHYDRAMINE; K 252A; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISORIENTATION; DRUG DETERMINATION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; DUODENUM CANCER; DYSPNEA; FATIGUE; HEADACHE; HUMAN; HYPOTENSION; INTRAVENOUS CATHETER; KIDNEY CANCER; LEIOMYOSARCOMA; MAXIMUM TOLERATED DOSE; MESOTHELIOMA; MUCOSA INFLAMMATION; NAUSEA; OBSERVATION; OVARY CANCER; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHLEBITIS; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; RASH; REFRACTORY PERIOD; RELIABILITY; RESPIRATORY FAILURE; SEMINOMA; SOLID TUMOR; STANDARD; THROMBOCYTOPENIA; TITRIMETRY; URTICARIA; UTERINE CERVIX CANCER; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARBAZOLES; COHORT STUDIES; DIPEPTIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; HYPOTENSION; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PRODRUGS; RECEPTOR PROTEIN-TYROSINE KINASES; TIME FACTORS;

EID: 10244241837     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DRUG.0000036687.26604.8c     Document Type: Article

References (24)

1. Miknyoczki SJ, Wan W, Chang H, Dobrzanski P, Ruggeri BA, Dionne CA, Buchkovich K: The neurotrophin-trk receptor axes are critical for growth and progression of human prostatic carcinoma and pancreatic ductal adenocarcinoma xenografts in nude mice. Clin Cancer Res 8: 1924-1931, 2002
2. Weeraratna AT, Arnold JT, George DJ, DeMarzo A, Isaacs JT: Rational basis for trk inhibition therapy for prostate cancer. Prostate 45: 145-153, 2000
3. Pflug BR, Dionne C, Kaplan DR, Lynch J, Djakiew D: Expression of a Trk high affinity nerve growth factor receptor in the human prostate. Endocrinology 136: 262-268, 1995
4. Xu X, Tahan SR, Pasha TL, Zhang PJ: Expression of neurotrophin receptor Trk-C in nevi and melanomas. J Cutan Pathol 30: 318-322, 2003
5. Marchetti D, Parikh N, Sudol M, Gallick GE: Stimulation of the protein tyrosine kinase c-Yes but not c-Src by neurotrophins in human brain-metastatic melanoma cells. Oncogene 16: 3253-3260, 1998
6. Marchetti D, Menter D, Jin L, Nakajima M, Nicolson GL: Nerve growth factor effects on human and mouse melanoma cell invasion and heparanase production. Int J Cancer 55: 692-699, 1993
7. Koizumi H, Morita M, Mikami S: Immunohistochemical analysis of TrkA neurotrophin receptor expression in human nonneuronal carcinomas. Pathol Int 48: 93-101, 1998
8. McGregor LM, McCune BK, Graff JR, McDowell PR, Romans KE, Yancopoulos GD, Ball DW, Baylins B, Nelkin BD: Roles of Trk family neurotrophin receptors in medullary thyroid carcinoma development and progression. Proc Natl Acad Sci USA 96: 4540-4545, 1999
9. Eggert A, Ikegaki N, Liu XG, Brodeur GM: Prognostic and biological role of neurotrophin-receptor TrkA and TrkB in neuroblastoma. Klin Padiatr 212: 200-205, 2000
10. Nakagawara A, Azar CG, Scavarda NJ, Brodeur GM: Expression and function of TRK-B and BDNF in human neuroblastomas. Mol Cell Biol 14: 759-767, 1994
11. Raffioni S, Bradshaw RA, Buxser SE: The receptors for nerve growth factor and other neurotrophins. Annu Rev Biochem 62: 823-850, 1993
12. Dabrow MB, Francesco MR, McBrearty FX, Caradonna S: The effects of platelet-derived growth factor and receptor on normal and neoplastic human ovarian surface epithelium. Gynecol Oncol 71: 29-37, 1998
13. Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M, Oberg K: Expression and prognostic significance of platelet-derived growth factor and its receptor in epithelial ovarian neoplasms. Cancer Res 53: 4550-1554, 1993
14. Camorrato AM, Jani JP, Angeles TS, Maroney AC, Sanders CY, Murakata C, Neff NT, Vaught JL, Isaacs JT, Dionne CA: CEP-751 inhibits trk receptor tyrosine kinase activity in vitro and exhibits anti-tumor activity. Int J Cancer 72: 673-679, 1997
15. Simon R, Freidlin B, Rubenstein L, Arbuck SG, Collins J, Christian MC: Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst 89: 1138-1147, 1997
16. Yano H, Chao MV: Mechanisms of neurotrophins receptor vesicular transport. J Neurobiol 58: 244-257, 2004
17. Slominski A, Wortsman J: Neuroendocrinology of the skin. Endocr Rev 21: 457-487, 2000
18. Donovan MJ, Miranda RC, Kraemer R, McCaffrey TA, Tessarollo L, Mahadeo D, Sharif S, Kaplan DR, Tsoulfas P, Parada L. Neurotrophin and neurotrophins receptors in vascular smooth muscle cells. Regulation of expression in response to injury. Am J Pathol 147: 309-324, 1995
19. Babb J, Rogatko A, Zacks S: Cancer phase I clinical trials: Efficient dose escalations with overdose control. Stat Med 17: 1103-1120, 1998
20. O'Quigley J, Pepe M, Fisher L: Continual reassessment method: A practical design for phase I clinical trials in cancer. Biometrics 46: 33-48, 1990
21. Collins JM, Zaharko DS, Dedrick RL, Chabner BA: Potential roles for preclinical pharmacology in phase I clinical trials. Cancer Treat Rep 70: 73-80, 1986
22. Dent SF, Eisenhauer EA: Phase I trial design: Are new methodologies being put into practice? Ann Oncol 7: 561-566, 1996
23. Von Hoff DD, Turner J: Response rates, duration of response and dose response effects in phase I studies of antineoplastics. Invest New Drugs 9: 115-122, 1991
24. Smith BD, Levis M, Beran M, Giles F, Brown P, Russell L, Hellriegel E, Dauses T, Allebach J, Small D: Single agent CEP-701, a novel FLT3 inhibitor, shows initial response in patients with refractory acute myeloid leukemia. Proc ASCO 22: 194, 2003 (Abstract)